The new business will provide development and manufacturing services for complex small molecules, including HPAPIs, peptides, ADC payloads, and linkers.
The agreement gives WuXi Biologics access to Transcenta’s intensified continuous bioprocessing platform for CMC development and manufacturing programs.
The program, which is expected to begin in Q4 2026, will transfer and scale eXoZymes’ N-trans-caffeoyltyramine production process at Curia facilities in Spain and Italy.
The $94 million investment will add manufacturing space and two aseptic fill-finish lines at its Caponago site, with total capacity to reach 500 million units annually.
The automated production suite has reduced scrap and invalid cartridge rates while increasing production capacity and labor productivity, according to the company.
The biologics CDMO completed process development, regulatory submission, and cGMP manufacturing of clinical material for the government-backed antibody program.
The 72,300-square-foot Hamilton, Ontario facility increases the company’s manufacturing capacity more than tenfold and supports clinical through commercial production.
The investment will add suites at the CDMO’s Sunderland facility, increasing the total from six to 10, and expanding commercial active pharmaceutical ingredient production.
The CRDMO added 70,000 square feet to the facility and isolated filling lines for syringes, cartridges, and vials, as well as lyophilization and packaging capabilities.
The CDMO’s Texas facility has supported six client programs expected to reach Investigational New Drug submission this year, following its 100th GMP batch in July.
The agreement with a global pharmaceutical company covers technical transfer activities for a marketed injectable product and is expected to begin generating revenue in 2028.
The 3,500-square-meter Vilnius facility includes up to 20 independent cGMP manufacturing lines for cell therapies and personalized medicines, according to the CDMO.
The Santiago facility received EXCiPACT certification for pharmaceutical excipient manufacturing covering commercial-scale QS-21 and other saponin fractions.
The new drug product facility can produce up to eight million vials annually of liquid or lyophilized bioconjugates for clinical and commercial programs.
The facility will more than triple Evonik’s Vancouver manufacturing capacity for lipid-based drug products, with production planned to begin by the end of 2029.
The new 225,000-square-foot facility in Whitestown is expected to expand its radiopharmaceutical manufacturing capacity and create up to 100 jobs by 2029.
The 120,000-liter biologics manufacturing facility in Songdo achieved the rating under South Korea’s Green Standard for Energy and Environmental Design.
The new Bilbao center adds mRNA drug substance, lipid nanoparticle formulation, and GMP drug product manufacturing capabilities to the company’s genetic medicines operations.
The expanded agreement gives viral vector developers access to research-use and GMP-grade synthetic DNA for cell and gene therapy development programs.
The agreement covers technology transfer, process development, scale-up, validation, commercial manufacturing, and long-term supply across multiple markets.